Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VB-201 in Patients with Inflammatory Biomarkers
NCT01159730Phase 2Completed
- Sponsor
- VBL Therapeutics
- Start
- Oct 2010
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of VB-201 in atherosclerosis, inflammation, sponsored by VBL Therapeutics. Started Oct 2010; status: completed.
02
Drugs
VB-201
03
Conditions
atherosclerosisinflammation
Beyond the preview
Go deeper on NCT01159730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01159730.